Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 4

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 4
---
 to the exercise price of the Series L Warrants and resulting
increase in the Depositary Shares underlying the Series L Warrants will be subject to a floor price. The floor price will be equal to
20% of the most recent NASDAQ Official Closing Price of the Depositary Shares preceding execution of the Underwriting Agreement.

If
all of the Series L Warrants offered to investors in this offering, including those subject to the underwriter’s overallotment option
for Series L Warrants, are exercised using the “zero exercise price” option at the floor price of the Series L Warrants, an
aggregate of Depositary Shares would be issued upon such “zero exercise price” option without payment to the Company of any
additional cash.

Please see the section of
this prospectus entitled “Description of the Securities we are Offering” for further information.

We are also offering the opportunity
to purchase, if the purchaser so chooses in lieu of Units, up to pre-funded units, or the Pre-Funded Units, to purchasers whose purchase
of Units in this offering would otherwise result in the purchaser, together with its affiliates, beneficially owning more than 4.99% (or,
at the election of the purchaser, 9.99%) of our outstanding Ordinary Shares immediately following the consummation of this offering. Each
Pre-Funded Unit consists of (i) one pre-funded warrant exercisable for one Depositary Share, or a Pre-Funded Warrant, and (ii) one Series
L Warrant. Subject to limited exceptions, a holder of Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded
Warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election of the holder, up
to 9.99%) of the number of Ordinary Shares outstanding immediately after giving effect to such exercise. The purchase price of each Pre-Funded
Unit will be equal to the price per Unit being sold to the public in this offering, minus $0.0001, and the exercise price of each Pre-Funded
Warrant included in the Pre-Funded Unit will be $0.0001 per Depositary Share. The Pre-Funded Warrants will be immediately exercisable
(subject to the beneficial ownership cap) and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

The Depositary Shares and Pre-Funded Warrants, and the